MedPath

Aripiprazole versus risperidone in the treatment of children and adolescents with tic disorders

Phase 3
Conditions
Tic disorder.
Tic disorders
Registration Number
IRCT201301053930N17
Lead Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

children and adolescents aged 6 to 18 years; total score of YGTS more than 21. Exclusion criteria: Marked general medical condition; hypersensitivity to the medications.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Yale global tic severity scale. Timepoint: Every 4 weeks. Method of measurement: interview.
Secondary Outcome Measures
NameTimeMethod
Adverse effects checklist. Timepoint: every 4 weeks. Method of measurement: checklist.
© Copyright 2025. All Rights Reserved by MedPath